Article

Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria

Harvard University, Cambridge, Massachusetts, United States
Journal of Biological Chemistry (Impact Factor: 4.6). 05/2003; 278(15):12605-8. DOI: 10.1074/jbc.C300012200
Source: PubMed

ABSTRACT There are about 2.5 million glomeruli in the kidneys each consisting of a barrel of glomerular basement membrane surrounded by glomerular endothelial cells on the inside and glomerular epithelial cells with established foot processes (podocytes) on the outside. Defects in this filtration apparatus lead to glomerular vascular leak or proteinuria. The role of vascular endothelial growth factor (VEGF) in the regulation of glomerular vascular permeability is still unclear. Recent studies indicate that patients receiving anti-VEGF antibody therapy may have an increased incidence of proteinuria. In a different setting, pregnancies complicated by preeclampsia are associated with elevated soluble VEGF receptor 1 protein (sFlt-1), endothelial cell dysfunction and proteinuria. These studies suggest that neutralization of physiologic levels of VEGF, a key endothelial survival factor, may lead to proteinuria. In the present study, we evaluated the potential of anti-VEGF neutralizing antibodies and sFlt-1 in the induction of proteinuria. Our studies demonstrate that anti-VEGF antibodies and sFlt-1 cause rapid glomerular endothelial cell detachment and hypertrophy, in association with down-regulation of nephrin, a key epithelial protein in the glomerular filtration apparatus. These studies suggest that down-regulation or neutralization of circulating VEGF may play an important role in the induction of proteinuria in various kidney diseases, some forms of cancer therapy and also in women with preeclampsia.

0 Followers
 · 
176 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The onset of pregnancy implies the appearance of a new organ, the placenta. One main function of the placenta is to supply oxygen to the fetus via hemoproteins. In this review, we highlight the importance of the enzyme heme oxygenase-1 (HO-1) for pregnancy to be established and maintained. HO-1 expression is pivotal to promote placental function and fetal development, thus determining the success of pregnancy. The deletion of the gene Hmox1 in mice leads to inadequate remodeling of spiral arteries and suboptimal placentation followed by intrauterine growth restriction (IUGR) and fetal lethality. A partial Hmox1 deletion leads to IUGR as well, with heterozygote and wild-type fetuses being born, but Hmox1-/- significantly below the expected Mendelian rate. This strong phenotype is associated with diminished number of pregnancy-protective uterine natural killer (uNK) cells. Pregnant heterozygote females develop gestational hypertension. The protective HO-1 effects on placentation and fetal growth can be mimicked by the exogenous administration of carbon monoxide (CO), a product of heme catalyzed by HO-1. CO application promotes the in situ proliferation of uNK cells, restores placentation and fetal growth, while normalizing blood pressure. Similarly, HO-1 inhibition provokes hypertension in pregnant rats. The HO-1/CO axis plays a pivotal role in sustaining pregnancy and aids in the understanding of the biology of pregnancy and reveals a promising therapeutic application in the treatment of pregnancy complications.
    Frontiers in Pharmacology 12/2014; 5. DOI:10.3389/fphar.2014.00291
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Glomerular VEGF expression is critical for the maintenance and function of an intact filtration barrier. Alterations in glomerular VEGF bioavailability result in endothelial as well as in podocyte damage. Renal involvement in preeclampsia includes proteinuria, podocyturia, elevated blood pressure, edema, glomerular capillary endotheliosis, and thrombotic microangiopathy. At least the renal signs, symptoms, and other evidence can sufficiently be explained by reduced VEGF levels. The aim of this paper was to summarize our pathophysiological understanding of the renal involvement of preeclampsia and point out similarities to the renal side effects of VEGF-ablation therapy.
    Journal of pregnancy 01/2011; 2011:176973. DOI:10.1155/2011/176973
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Les médicaments anti-angiogéniques (médicaments anti-Vascular Endothelial Growth Factor (VEGF) sur le marché : bévacizumab [Avastin®], sunitinib [Sutent®], sorafénib [Néxevar®]) sont de plus en plus utilisés dans le traitement de certains cancers (côlon, sein, poumon, foie et rein). Leurs effets secondaires sont mal connus des médecins. L’hypertension artérielle (HTA) est l’effet indésirable le plus fréquent. Son incidence dépend de la définition de l’HTA utilisée, de la molécule et la dose. Elle est généralement contrôlable par les traitements antihypertenseurs et compromet rarement la poursuite du traitement. Plus rarement, elle peut avoir des conséquences graves (HTA maligne, leucoencéphalopathie postérieure réversible, accident vasculaire cérébral…). Des atteintes rénales sont moins fréquentes : protéinurie modérée le plus souvent, réversible, et plus rarement, syndrome néphrotique, insuffisance rénale aiguë, glomérulopathie proliférative, néphrite interstitielle et microangiopathie thrombotique. Allongement de l’espace QT et insuffisance cardiaque ont été observés avec des tinibs. Sur le plan thérapeutique : (1) Avant l’administration d’une première dose d’un traitement anti-angiogénique, il ne faut pas retarder l’administration d’une première dose ou administrer un traitement anti hypertenseur en raison d’une pression artérielle (PA) élevée ; (2) Le bilan initial comporte une mesure de la PA réalisée avec un appareil de mesure validé soit par le médecin traitant, soit au mieux en automesure tensionnelle (« Règle des 3 », HAS HTA 2005 http://www.has-sante.fr), soit en mesure ambulatoire de la PA, (appareil de mesure huméral validé (liste : http://afssaps.sante.fr/) ; idéalement, ces appareils d’auto mesure tensionnelle et le carnet de suivi devraient être fournis par le laboratoire pharmaceutique qui met en vente le médicament anti-angiogénique ; (3) La bandelette urinaire (et le cas échéant, quantification de la protéinurie), l’estimation de la fonction rénale (formule de MDRD simplifiée plutôt que Cockcroft et Gault) doit être effectuée avant traitement et au cours du suivi ; (4) La prise en charge thérapeutique se fait conformément aux recommandations (HAS HTA 2005 : http://www.has-sante.fr/) ; (5) La surveillance et la prise en charge thérapeutique se feront au mieux dans le cadre d’un travail en réseau comprenant médecin généraliste, oncologue, cardiologue et néphrologue.
    Néphrologie & Thérapeutique 12/2008; 4(7):602-615. DOI:10.1016/j.nephro.2008.10.002 · 0.55 Impact Factor